Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AUTL |
---|---|---|
09:32 ET | 10194 | 3.5 |
09:34 ET | 14106 | 3.47 |
09:36 ET | 200 | 3.455 |
09:38 ET | 5100 | 3.48 |
09:39 ET | 5408 | 3.52 |
09:41 ET | 15445 | 3.5 |
09:43 ET | 100 | 3.51 |
09:45 ET | 4300 | 3.49 |
09:48 ET | 650 | 3.54 |
09:50 ET | 500 | 3.53 |
09:52 ET | 800 | 3.55 |
09:54 ET | 2588 | 3.54 |
09:56 ET | 1200 | 3.56 |
09:57 ET | 1319 | 3.56 |
09:59 ET | 1196 | 3.55 |
10:01 ET | 2530 | 3.55 |
10:03 ET | 2500 | 3.545 |
10:06 ET | 15097 | 3.51 |
10:08 ET | 550 | 3.525 |
10:10 ET | 4442 | 3.49 |
10:12 ET | 200 | 3.48 |
10:14 ET | 1398 | 3.485 |
10:15 ET | 800 | 3.47 |
10:17 ET | 2900 | 3.475 |
10:19 ET | 2538 | 3.475 |
10:21 ET | 3749 | 3.46 |
10:24 ET | 4335 | 3.475 |
10:26 ET | 2100 | 3.465 |
10:28 ET | 2876 | 3.455 |
10:30 ET | 14696 | 3.445 |
10:32 ET | 4026 | 3.455 |
10:33 ET | 1800 | 3.435 |
10:35 ET | 1500 | 3.44 |
10:37 ET | 453 | 3.445 |
10:39 ET | 1444 | 3.435 |
10:42 ET | 24675 | 3.4116 |
10:44 ET | 1605 | 3.41 |
10:46 ET | 1200 | 3.42 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Autolus Therapeutics PLC | 925.8M | -2.8x | --- |
Cassava Sciences Inc | 925.5M | -16.3x | --- |
Cullinan Therapeutics Inc | 946.4M | -5.0x | --- |
Tyra Biosciences Inc | 892.1M | -9.5x | --- |
Enliven Therapeutics Inc | 1.0B | -10.6x | --- |
Rapport Therapeutics Inc | 830.3M | -15.6x | --- |
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $925.8M |
---|---|
Revenue (TTM) | $10.5M |
Shares Outstanding | 266.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.10 |
EPS | $-1.21 |
Book Value | --- |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 88.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,670.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.